Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is essential for maintaining normal function of the adult heart and is known to play an important role in myocardial remodeling. In the present study, we observed that heart-specific HB-EGF transgenic (TG) mice had systolic dysfunction with decreased fractional shortening (FS%), increased end-systolic diameter (LVIDs) at 5 months of age, increased heart fibrosis, and increased mRNA expression of Col1α1 and Col3α1 at 1, 3, 5 and 7 months of age compared to nontransgenic (NTG) littermates. However, the left ventricular anterior wall thickness at end-systole (LVAWs) of the TG mice was not different than the NTG mice. Phosphorylation levels of Akt, mTor and p70s6k were increased due to HB-EGF expression in TG mice compared with the NTG mice at 3 and 7 months of age. Additionally, activated Akt, mTor and p70s6k were co-localized with vimentin to cardiac fibroblasts isolated from TG mice. Furthermore, HB-EGF significantly increased phosphorylation levels of Akt, mTor and p70s6k and increased expression of type I collagen in cultured primary cardiac fibroblasts. Rapamycin (Rapa) and CRM197, inhibitors of mTor and HB-EGF respectively, could inhibit the expression of type I collagen in the cultured primary cardiac fibroblasts and Rapa suppressed interstitial fibrosis of the heart tissues in vivo. In addition, a BrdU assay showed that HB-EGF increased proliferation of cardiac fibroblasts by 30% compared with cells without HB-EGF treatment. HB-EGF-induced proliferation was completely diminished in the presence of Rapa. These results suggest that HB-EGF induced heart fibrosis and proliferation of cardiac fibroblasts occurs through activation of the Akt/mTor/p70s6k pathway.
References
[1]
Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M (1991) A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936–939.
[2]
Higashiyama S, Lau K, Besner GE, Abraham JA, Klagsbrun M (1992) Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem 267: 6205–6212.
[3]
Iwamoto R, Mekada E (2000) Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev 11: 335–344.
[4]
Higashiyama S, Abraham JA, Klagsbrun M (1993) Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 122: 933–940.
Vaughan TJ, Pascall JC, Brown KD (1992) Tissue distribution of mRNA for heparin-binding epidermal growth factor. Biochem J 287: 681–684.
[7]
Abraham JA, Damm D, Bajardi A, Miller J, Klagsbrun M, et al. (1993) Heparin-binding EGF-like growth factor: characterization of rat and mouse cDNA clones, protein domain conservation across species, and transcript expression in tissues. Biochem Biophys Res Commun 190: 125–133.
[8]
Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, et al. (2003) Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A 100: 3221–3226.
[9]
Marikovsky M, Breuing K, Liu PY, Eriksson E, Higashiyama S, et al. (1993) Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci U S A 90: 3889–3893.
[10]
Tokumaru S, Higashiyama S, Endo T, Nakagawa T, Miyagawa JI, et al. (2000) Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J Cell Biol 151: 209–220.
[11]
Shirakata Y, Kimura R, Nanba D, Iwamoto R, Tokumaru S, et al. (2005) -Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. J Cell Sci 118: 2363–2370.
[12]
Mine N, Iwamoto R, Mekada E (2005) HB-EGF promotes epithelial cell migration in eyelid development. Development 132: 4317–4326.
[13]
Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, et al. (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35–40.
[14]
Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, et al. (1995) Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 95: 404–411.
[15]
Takemura T, Hino S, Kuwajima H, Yanagida H, Okada M, et al. (2001) Induction of collecting duct morphogenesis in vitro by heparin-binding epidermal growth factor-like growth factor. J Am Soc Nephrol 12: 964–972.
[16]
Das SK, Wang XN, Paria BC, Damm D, Abraham JA, et al. (1994) Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: a possible ligand for interaction with blastocyst EGF-receptor in implantation. Development 120: 1071–1083.
[17]
Xie H, Wang H, Tranguch S, Iwamoto R, Mekada E, et al. (2007) Maternal heparin-binding-EGF deficiency limits pregnancy success in mice. Proc Natl Acad Sci U S A 104: 18315–18320.
[18]
Lemjabbar H, Basbaum C (2002) Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 8: 41–46.
[19]
Fu S, Bottoli I, Goller M, Vogt PK (1999) Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc Natl Acad Sci U S A 96: 5716–5721.
[20]
Taniyama Y, Morishita R, Aoki M, Hiraoka K, Yamasaki K, et al. (2002) Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 40: 47–53.
[21]
Su EJ, Cioffi CL, Stefansson S, Mittereder N, Garay M, et al. (2003) Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularization. Am J Physiol Heart Circ Physiol 284: H1429–1440.
[22]
Ushikoshi H, Takahashi T, Chen X, Khai NC, Esaki M, et al. (2005) Local overexpression of HB-EGF exacerbates remodeling following myocardial infarction by activating noncardiomyocytes. Lab Invest 85: 862–873.
[23]
Tanaka N, Masamura K, Yoshida M, Kato M, Kawai Y, et al. (2002) A role of heparin-binding epidermal growth factor-like growth factor in cardiac remodeling after myocardial infarction. Biochem Biophys Res Commun 297: 375–381.
[24]
Fujino T, Hasebe N, Fujita M, Takeuchi K, Kawabe J, et al. (1998) -Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats. Cardiovasc Res 38: 365–374.
[25]
Kirkland G, Paizis K, Wu LL, Katerelos M, Power DA (1998) Heparin-binding EGF-like growth factor mRNA is upregulated in the peri-infarct region of the remnant kidney model: in vitro evidence suggests a regulatory role in myofibroblast transformation. J Am Soc Nephrol 9: 1464–1473.
[26]
Means AL, Ray KC, Singh AB, Washington MK, Whitehead RH, et al. (2003) Overexpression of heparin-binding EGF-like growth factor in mouse pancreas results in fibrosis and epithelial metaplasia. Gastroenterology 124: 1020–1036.
[27]
Mulder GM, Melenhorst WB, Celie JW, Kloosterhuis NJ, Hillebrands JL, et al.. (2011) ADAM17 up-regulation in renal transplant dysfunction and non-transplant-related renal fibrosis. Nephrol Dial Transplant.
[28]
Blaine SA, Ray KC, Branch KM, Robinson PS, Whitehead RH, et al. (2009) Epidermal growth factor receptor regulates pancreatic fibrosis. Am J Physiol Gastrointest Liver Physiol 297: G434–441.
[29]
Kiso S, Kawata S, Tamura S, Inui Y, Yoshida Y, et al. (2003) Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomy. Gastroenterology 124: 701–707.
Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, et al. (1999) Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99: 2750–2756.
[32]
Wei S, Chow LT, Shun IO, Qin L, Sanderson JE (1999) Left and right ventricular collagen type I/III ratios and remodeling post-myocardial infarction. J Card Fail. 5: 117–126.
[33]
Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, et al. (2008) Membrane-anchored growth factors, the epidermal growth factor family: Beyond receptor ligands. J Cancer Sci 99: 214–220.
[34]
Jin K, Mao XO, Del Rio Guerra G, Jin L, Greenberg DA (2005) Heparin-binding epidermal growth factor-like growth factor stimulates cell proliferation in cerebral cortical cultures through phosphatidylinositol 3′-kinase and mitogen-activated protein kinase. J Neurosci Res 81: 497–505.
[35]
Reynolds CM, Eguchi S, Frank GD, Motley ED (2002) Signaling mechanisms of heparin-binding epidermal growth factor-like growth factor in vascular smooth muscle cells. Hypertension 39: 525–529.
[36]
Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253–262.
[37]
Xiang X, Zhao J, Xu G, Li Y, Zhang W (2011) mTOR and the differentiation of mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai) 43: 501–510.
[38]
Murakami M, Ichisaka T, Maeda M, Oshiro N, Hara K, et al. (2004) mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 24: 6710–6718.
[39]
Zhu J, Wu J, Frizell E, Liu SL, Bashey R, et al. (1999) Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117: 1198–1204.
[40]
Biecker E, De Gottardi A, Neef M, Unternahrer M, Schneider V, et al. (2005) Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther 313: 952–961.
[41]
Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J (2006) Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 45: 786–796.
[42]
Bridle KR, Li L, O’Neill R, Britton RS, Bacon BR (2006) Coordinate activation of intracellular signaling pathways by insulin-like growth factor-1 and platelet-derived growth factor in rat hepatic stellate cells. J Lab Clin Med 147: 234–241.
[43]
Bridle KR, Popa C, Morgan ML, Sobbe AL, Clouston AD, et al. (2009) Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl 15: 1315–1324.
[44]
Gabele E, Reif S, Tsukada S, Bataller R, Yata Y, et al. (2005) The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol Chem 280: 13374–13382.
[45]
Shegogue D, Trojanowska M (2004) Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 279: 23166–23175.
[46]
Wang S, Wilkes MC, Leof EB, Hirschberg R (2010) Noncanonical TGF-beta pathways, r and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 298: F142–149.
[47]
Gordon JW, Ruddle FH (1981) Integration and stable germ line transmission of genes injected into mouse pronuclei. Science 214: 1244–1246.
[48]
Juan F, Wei D, Xiongzhi Q, Ran D, Chunmei M, et al. (2008) The changes of the cardiac structure and function in cTnTR141W transgenic mice. Int J Cardiol 128: 83–90.
[49]
Caiazza F, Harvey BJ, Thomas W (2010) Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediatesestrogen-dependent breast cancer cell growth. Mol Endocrinol 24: 953–968.
[50]
Jonathan M Shillingford, Klaus B Piontek, Gregory G Germino, Thomas Weimbs (2010) Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1. J Am Soc Nephrol 21: 489–497.
